Welcome to Gellar Fan, your newest online source about Sarah Michelle Gellar. Here you will find the latest news & updates about Sarah, as well as extensive information, media content and our ever growing photo gallery. Don't forget to bookmark this site and remember to keep checking back for more updates. Enjoy and thanks for stopping by!

Posted by on January 16th, 2021


“I see a lot of support for novel technologies that are simply a derivative of what’s been around for a decade or so,” he says. Garth McCallum-Keeler, managing partner in the San Francisco office of Calcium, says one of the most interesting ways in which technology is changing research and development is through the use of big data or metadata to inductively search for possible linkages between drugs and cell surface markers. When budget cuts are made, external technology collaborations are often the first to be cut. “The level of engagement with the FDA for products receiving this designation is great, which could allow the product development to be quicker and market entry earlier.”, Dr. Ryan says the increased interaction with the FDA, especially early in the development process, is an important factor for enabling innovation. Disruptive Technologies in Pharma is a conference that provides an insight on how digital is impacting and disrupting pharma, from the perspective of the digitalization of the product and the digital customer/consumer. “Think of the power packed onto microchips, the way a 3D printer can create items seemingly out of thin air, or the ability of handheld devices to handle increasingly complex tasks. “An RNAi approach may provide treatment ­options or even cures for many serious diseases that have been undruggable thus far,” says Vincent ­Anzalone, VP, investor relations, Arrowhead Research. The business of outsourcing will, itself, be reinvented. “The traditional models that have long disappointed will be replaced by laboratory human tissue systems that are capable of recreating healthy and disease biology to more accurately predict human response at human-relevant dosages,” he says. In order to integrate and bring innovation to the market, pharma companies must consider a number of strategies, including adopting and shifting to a fail-fast and frugal mentality. We serve dozens of customers in various industries, all with different business cases and deployment contexts. Today for every $1 billion spent the result is one product, where the output was 10 products years ago from that same investment.”. The ability to innovate, industry leaders agree, will be a critical factor in a pharmaceutical company’s success in the future. Our industry thought leaders identified several areas where multiple factors are converging that will lead to innovative treatments in the future. Fill out the form below and we will email you a new one. ” Dr. Robert Ryan /  Scioderm, “Treating cancer locally versus systemically is particularly challenging since cancer is by ­definition a systemic disease; the local ­treatment standard of care often fails. In 2019 Deep Dive will have special focuses on disruptive technologies in pharma, R&D innovation, market access & commercialisation, oncology, … “We will need to understand combinations of drugs, both small molecules and highly specific biological agents such as ADC, that will give synergistic ­efficacy, without increasing toxicity. 3. “For example, the trend toward wearables will continue to rise over the next 10 years,” he says. Digital Edition Extra Copies Reprints Subscriptions. But several profoundly disruptive forces at work in the industry today will likely halt that trend. Subscribe to future issues of Deep Dive. SMi group presents the launch of the inaugural Disruptive Technologies in Pharma conference taking place in London on 20th-21st January, 2020. /* Content Template: Articles - end */ “Healthcare innovation cannot happen in a silo,” she says. While this number pales in comparison with Cannabis's more established peers like the Alcohol industry and the Pharmaceutical industry, cannabis is both a newer player to the game, and has a unique aspect to it – cannabis can weave itself into most industries. Industry leaders say recently, great strides have been made and novel approaches have tackled shortcomings such as delivery and side effects. “True ­innovation requires pharma leadership to ­recognize that maintenance of status quo and incremental tech advances are unlikely to lead to timely substantial breakthroughs in ­therapies for patients in need. “We have a healthcare system where physicians hold the intellectual capital, payers hold the purse strings, and patients control their care. Matthew Howes, senior VP, head of strategic services, at Palio+Ignite, an inVentiv Health company, says one of the most imminent threats the healthcare industry needs to prepare for is data security. VR and AR can be game changers in terms of brand preference and recasting the relationship between the rep and the doctor, the pill and the patient. Frost & Sullivan, in a report in May 2014, finds that technologies such as nanobots, combination devices, electroceuticals, and genome sequencing will have a tremendous impact on the industry, and by 2020 the 3D printing market will be $7.1 billion with medical and dental accounting for 16% of that. “Companies developing new classes of biologic therapeutics need to invest the time and effort and resources required to achieve a deep understanding of the mechanism of action of their treatments,” Mr. Aberman continues. Without the freedom to take risks, innovation can’t succeed, and risks don’t come without a ­certain amount of failure. “If we are truly taking risks to innovate then some ideas and innovations will fail by definition,” he says. “And while such commitment to innovation continues to gain momentum, the industry must take advantage of the growing ­willingness to rethink existing processes and bring about meaningful change.”. The conference will provide industry leaders with the […] Groundbreaking research will increasingly come from new places as the playing field levels.”. “Eureka moments rarely occur in isolation,” he says. Moving innovation from the lab to the clinic to the market requires champions. “As one example, NCBIs — the National Center for Biotechnology Information — GEO registry of microarrays now allows researchers to search across an aggregate national database to identify possible associations; these known associations and known markers of disease activity can then be assessed via traditional clinical research approaches,” he says. Tags: Precision Medicine; Organoids; Corning Life Sciences; Personalized Medicines; 3D Cell Culture; Personalized treatments are poised to have a tremendous positive impact for patients across disease indications. “It is something that, from a packaging and delivery systems standpoint, we are evaluating as a potential way to build efficiencies into some of our processes,” she says. In the first issue of Deep Dive for 2019, we look at disruptive technologies in pharma, how they’re changing medicine, research and development, and healthcare, and how the pharmaceutical industry is responding to these momentous shifts. Treating ­different cancers locally with another drug safely and effectively is a paradigm shift in treating ­disease. RNA Interference RNA interference (RNAi) is used by cells to regulate protein expression. 2. This disjointed approach makes solving our industry’s problems difficult. “Most innovations are the collisions of multiple ideas or the timing of an idea versus a specific context/environment. Payors and governments have an ever sharper focus on managing costs while delivering improved patient outcomes, putting an even greater onus on pharma companies to demonstrate the value of their drugs in the real world—not just in randomized controlled trials—if they are to retain market access and premium pricing. Designing a lean governance and project management function can improve decision-making and support scientists to focus on the discovery of breakthrough innovations. Strengthen collaboration and adapt the R&D model to support innovation across networks. “Today, such varied and proprietary systems are hindering the implementation of common standards. Data disruption and applying ‘enabled intelligence’ to convert the promise shown in clinical trials into real-world success, Defining the digital therapeutics opportunity As technology and traditional healthcare converge, some trends in cutting-edge digital health innovation are emerging, Pharma in the age of acceleration × | The Medical Futurist × Get the week's top news shaping the future of medicine. ” Ibraheem Mahmood /  DrugDev, Alliances and Partnerships Will be Critical to Innovation in the Future. The use of data and technology is crucial to capturing and interpreting product information as it passes through the development process. Pharma in the age of acceleration. Getting the most out of a collaborative ­partnership will require proper joint ­development that will lead to licensing ­agreements earlier in the product ­development process. Scientists are motivated by scientific ­discovery and the publication of their research in peer-reviewed journals. Some leaders have pointed to the positive changes taking place at regulatory agencies. ” James Powers /  HemoShear, “An RNAi approach may provide treatment options or even cures for many serious diseases that have been undruggable thus far.” Vincent Anzalone Arrowhead Research, “Technology is changing research and development through the use of big data or metadata to inductively search for possible linkages between drugs and cell surface markers. RNAi-based ­therapeutics have the potential to specifically silence gene ­expression, but initial attempts to develop drugs based on this technology have failed. Machine learning and pharma R&D . The age of digital medicine is here “If we look at a long-trend view, efficiency has dropped continuously over the last 60 years. Today’s methods for predicting safety and efficacy of new drug candidates haven’t changed much over the years with the same animal and cell models being used despite lack of success, says Brian Wamhoff, Ph.D., VP R&D at HemoShear. pharmaphorum’s digital magazine Deep Dive provides objective, issue-driven views, analysis, high-level interviews and unique research for pharmaceutical companies, biotech firms and the wider healthcare sector. The tremendous time and expense of the clinical process means some promising candidates are being delayed or left on the shelf, says Ibraheem Mahmood, president and CEO of DrugDev. Fear of change is common throughout the corporate world, but those industries that are highly regulated suffer from this paralysis more often, says Ari Schaefer, VP group account director at Klick Health. all rights reserved. Pharmaceutical companies need to foster this environment for scientists if they intend to recruit and retain top talent. Mr. de Vries says this means quickly adapting to emerging and rapidly changing technologies. Disruptive Technologies in Pharma 2020 Details Events 06 September 2019 20 - 21 January 2020, London, UK. “Such platforms can aggregate patient data across studies and drug programs, allowing life-sciences companies to benefit from quick and easy access to relevant, high-quality, and analysis-ready data. “Many companies have embraced this partnership opportunity, and many others should explore it,” he says. Those which have already triggered cultures to evolve and those which hold the potential to disrupt the current flow … “Breakthrough therapy designation can have a significant impact on a drug’s development pathway and corporate strategy,” says Robert Ryan, Ph.D., president and CEO of Scioderm. Instead of selecting top ­executives who came up through sales or ­research, companies are promoting people who can achieve operational or financial ­objectives. Disruptive Materials Pharma. It is highly unlikely in most diseases, including cancer, that a single agent will lead to a cure, says Lawson Macartney, Ph.D., president and CEO, Ambrx. The principles of clinical trial design and methods of validation haven’t really changed since the 1940s, says Stan Lapidus, president, CEO and founder, SynapDx. “It’s no longer good enough to be ahead of the curve; competitors can catch up too fast. “Often, this involves making the most of limited corporate resources,” he says. Although three-dimensional printing may have the ability to produce an item, the industry must ask: does it ultimately function in the way it needs to? We need to tear down our siloed walls and commit to working collaboratively to improving outcomes.”. 5. “Broadly accepted methods for clinical trial designs that allow for the creation of large data sets by the aggregation of smaller sets from different laboratories will be the key to major breakthroughs in omics-scale medicine. Heads of innovation, communication and digital strategy in pharma reflected at Frontiers Health 2018 on the implications of technological changes, Company profile: Evidera The pharma packaging industry has been dominated by three primary players for years. True innovation only happens when people talk to each other, when the various parts of the health system come together to understand each other’s challenges, spark dialogue, and collaborate on solutions, says Lynn O’Connor Vos, CEO of ghg. “These new technologies are already making it possible to enable direct study of drug efficacy in the only context that matters: the human patient, without exposing patients to systemic toxicities,” he says. 1 ­factor for enabling innovation is courage. “As an industry, we need to adopt solutions that have the potential to dramatically lower ­development costs, reduce time to market, ­mitigate risks, engage patients and increase the probability of trial success,” he says. Peter Culpepper, chief operating officer, Provectus Biopharmaceuticals, says treating ­cancer is complex because there are many ­different types of cancers. ” Dr. Brian Wamhoff /  HemoShear, “Complementary partnerships also pertain to academic life-sciences R&D centers, which themselves are often struggling for survival. “What makes a difference is not so much these devices’ individual functions, but their interactivity and interoperability,” she says. “With the flexibility to interface with legacy systems, these technology solutions are equipped to support the complexity and rigorous needs of clinical research today,” he says. As new technologies are being incorporated into pharma it is crucial, we reflect on trends in cutting-edge innovation and explore new tech-enabled opportunities to cut costs and save time. Technologies that enable multi-drug studies without inducing systemic toxicities will release drug developers from the confines of poorly predictive preclinical models for human diseases.”. 6. Smart Pharma: How Technology is Disrupting the Pharmaceutical Industry May 18, 2018 New technologies such as big data and AI are revolutionising the pharmaceutical industry. “Infusing healthcare market expertise and knowledge of HCP adoption patterns into the technological development process will be critical not only for acceptance of these technologies but also essential for innovations that add immediate, real value to patient care,” he says. These 10 technologies will transform Pharma and we need to act now to reap the rewards in order to stay in business when they reach us. /* ----------------------------------------- */ 4. What future for pharma in a digital world? SMi Group. Could Lilly’s donanemab readout in Alzheimer’s boost Biogen’s prospects? It’s a top-to-toe disruption affecting everything from patient interaction with the health system, to how they are treated. The tech giants and telcos have created dedicated healthcare divisions to drive the connected and ‘always on’ experience that consumers are demanding from our industry.”. SUBSCRIBE. “Emerging strategies have managed delivery issues for RNAi therapeutics, enabling them to reach the proper target tissue/cells. Put those things together and there isn’t the same catalyst and process for change.”, Niklas Morton, VP, global biostatistics, programming and medical writing, PPD, says there needs to be a true commitment to innovation and a recognition that not all ideas will drive through to successful innovation. Since the world now stands on the fourth industrial revolution, disruptive technology is also evolving faster than ever. “The ability to have interactions with the FDA in a more frequent time frame than the current meeting requests is important for innovation,” he says. “Biotech companies need to maximize the opportunities for advancing pipeline candidates through clinical trials by pursuing programs in partnership with pharmaceutical and biopharmaceutical companies as well as on their own,” he says. NOTE: The content below contains the first few paragraphs of the printed article and the titles of the sidebars and boxes, if applicable. Organizations and industries need to cultivate and store ideas until the right collision or right-time/right-place moment.”. written by Patrick Burton on 09.08.2017 PharmaBoardroom’s readers were polled on what they felt was the most disruptive force in the pharmaceutical industry today. MHRA looks to AI to hunt for COVID-19 vaccine side effects, 5 ways digital health, and digital pharma, changed in 2020, Digital patient solutions: the secret to delivering and securing adoption, The Application Of Machine Learning To Field Insights, Machine-learning, robotics and biology to deliver drug discovery of tomorrow, Survey Finds Telehealth Is Convenient Alternative, Will Likely Continue Beyond the Pandemic. New technologies will drive innovation in the pharmaceutical industry in the years to come. “These and other capabilities will not only drive greater innovation in clinical research and development but enable us to make better and more informed strategic decisions,” he says. “The most innovative pharma companies will need to look beyond traditional R&D outlets to source new ideas. “A safe environment needs to exist where idea generation, proof of concept, and idea failure are supported; where enthusiastic leadership support and budgets can be accessed through a known process; and where project planning and data analysis are supported through corporate resources.”. 2. Newer technologies allow for access to real-time data, says Xavier Flinois, president of Parexel Informatics. Pharma companies that neglect to implement big data and AI will be left behind by those who capitalize on the opportunities the technologies represent. Developing a drug costs 10 times as much as it did 30 years ago and 100 times as much as it did 60 years ago. Pharmaceutical companies continued to externalize their research operations in 2013, increasing early-stage partnering activity with biotech companies and academic institutions, according to Burrill & Co. Of the $35.4 billion in potential value of partnering deals with disclosed values, $14.2 billion were discovery or preclinical collaborations. As the life-sciences industry continues to push the boundaries of existing clinical development models, companies, researchers, regulators and other stakeholders must all embrace change, says Glen de Vries, president of Medidata Solutions. In the coming year, and years to come, there will be new and more effective models emerging that will more reliably inform efficacy and safety decisions, and improve patient outcomes, Dr. Wamhoff says. The funders, the Defense Advanced Research Projects Agency, were interested in implications for soldiers with PTSD, but there’s broader importance. These 10 technologies will transform Pharma and we need to act now to reap the rewards in order to stay in business when they reach us. And the structure of CRO/CMO relationships in pharma will be ­refashioned to route around the limitations and bottlenecks of traditional contract ­partnerships.”. /* ----------------------------------------- *//* ----------------------------------------- */ “Treating disease locally versus systemically is particularly challenging since ­cancer is by definition a systemic disease; the local treatment standard of care often fails. To overcome this challenge, Mr. de Vries says life-sciences organizations are adopting cloud-based technology solutions that offer an interoperable model based on service-oriented and standards-based architecture. December 9, 2020 PAP-Q4-20-CL-009. And it has become fundamental to business growth where companies need to implement this strategically. Sign-up for Daily News alerts. While it’s easy to think about the Internet of Things as wearables and platforms and 3D printers and data, it’s time to think bigger than that, says Wendy Blackburn, executive VP of Intouch Solutions. “New technology is often noted for its portability, ability to function independently of an existing infrastructure, and its high capability-to-cost ratio,” he says. Adapting to the changing healthcare ecosystem requires that companies start ­assessing the `value’ of a project from a patient perspective as early as possible in the R&D process. “The challenge is adapting the R&D paradigm so that the combination of therapies needed can be tailored for the specific patient,” he says. Technological advancement is an arena that sees many attempts at sparking revolution. ” Garth McCallum-Keeler /  Calcium, “To transform the business of ­clinical trials, we must create a ­uniform use of technology, a standard way of running trials. With 2021 right around the corner, you should know emerging startups that will impact the BioTech sector in the coming year. The wise R&D-based company will be looking hard at its ‘intrapreneurs’ and its extended R&D collaborations to optimize options, invest wisely in opportunities with very high risk, but balance the risk portfolio.”, Analyzing data captured by multiple, disparate IT systems remains a critical challenge to bringing a product to market, Mr. de Vries says. “We seem to have arrived at a breaking point where scientists and government officials are recognizing that the current paradigm is broken and a fundamental change in drug discovery and development is necessary if we are to improve the odds.”. Cells are sensitive creatures, and even small variations in the environment in which they are grown will affect them. “Fortunately, more and more managers, ­especially those in the C-suite, understand that we need to figure out how to plan and run studies differently,” he says. We all know this ratio but up to now have had to work within the confines of the existing assessment models. We develop selected drug products within a market niche facilitated by our proprietary drug delivery platform, the pharma-grade mesoporous magnesium carbonate (Pharma-MMC, further information available on the MMC Technology section). /* Content Template: Articles - start */ “It is also important for individual stakeholders, especially those conducting the trials, to find a way to invest or provide investment capabilities that allow innovation through use of disruptive technologies. “The efforts by the FDA have been with the new expedited pathway options to offer more proactive and timely communication, which again will have a positive impact on enabling innovation.”. Using real-time data will also increase data quality and, ultimately, improve outcomes. It is increasingly being used for simulated customizations for artificial intelligence applications, prosthetics, and drug manufacturing-related applications. For the pharma industry, the choice is simple – be disruptive or be disrupted. Its discovery has transformed the understanding of gene regulation and ways for ­researchers to manipulate it. The industry is experiencing a technology revolution and customer expectations are having huge demands on what is possible, says James Streeter, senior director, life sciences product strategy, Oracle Health Sciences. Many of the concerns pertaining to the implementation of digital solutions are grounded in a lack of understanding as opposed to a concern grounded in experience. “In the case of cell therapy, the process of manufacturing the cells has a huge ­impact on the product. “Part of the challenge, however, is that regulators typically take four to five years to clear the impact on patient safety and efficacy assessments with new technologies. Companies will have to embrace scientific advances and technologies to move new and innovative therapies forward. “The industry is looking to technology companies to handle all of the variant sources of data, as well as the large amount of data already produced to inform better study design and become more productive and efficient, while rationalizing costs,” he says. Material, chemical, and functional characteristics are also very important to the industry. “This will be a game changer, particularly for cancer drug development. Successful companies will embrace partnerships with nontraditional stakeholders in healthcare. Three-dimensional printing certainly has the potential to be a disruptive technology in many ways in the healthcare industry, says Fran DeGrazio, VP, global R&D, strategic program management and technical customer support, West Pharmaceutical Services. This type of analysis also takes into account the risk factors that could prove fatal to a patient. “Many immunotherapeutic approaches have shown promising results for the treatment of cancer. “Over the years, life-sciences companies have made substantial investments in a range of technology solutions from third-party vendors and customized internal IT systems to support R&D,” he says. Details. Defining the digital therapeutics opportunity. This establishment (commonly called "Big Glass") primarily produces borosilicate products, the technology … Bring the customer and patient to the heart of the R&D process. Failure to do so can doom trials and prevent development of a marketable product.”. Taking a macro perspective, she investigates how and through which channels, e.g. 3. As disruptive technologies get cheaper, it is important for the industry to work with regulators to secure their approval and adoption,” says Xavier Flinois, president of Parexel Informatics. Possible answers were big data and digitalization, patient-centricity, economic austerity, and advancements in supply chain management. “The ability to face the regulatory questions surrounding new technologies will always be an obstacle to overcome when implementing innovative approaches to existing problems,” he says. It takes guts to enable innovation in the traditionally ­conservative drug development industry.”. SMi Reports: Jessica Shull from Digital Therapeutics Alliance to present at Disruptive Technologies in Pharma conference in London on the 20th and 21st January The highly anticipated launch of the inaugural Disruptive Technologies in Pharma conference is set to take place in London on 20th-21st January 2020. Those who thought no human was involved were more open and honest about their symptoms and experiences. Syneos Health tracks the future paths for healthcare technology to identify what will be truly disruptive for the pharmaceutical industry, Opening doors in pharmaceutical development Dr. Norchi says the complementary partnership conversation also pertains to academic life-sciences R&D centers, which themselves are often struggling for survival as a result of structural shifts in the funding environment. I believe this will change, and soon. Only 27% of health executives said their companies formally manage innovation, according to a recent study conducted by PwC. All you have to do is check your mail and you will be directed back to PharmaVOICE.com. It’s a top-to-toe disruption affecting everything from patient interaction with the health system, to how they are treated. Get free access to PharmaVOICE magazine, /* ----------------------------------------- */, PharmaVOICE Print and Digital Subscription, Disruptive Technology: The Keys to Pharmaceutical Innovation. “The sad truth is drug development is as inefficient as it’s ever been,” he says. “The research suggests that advances in artificial intelligence and human-machine interfaces could have a remarkable, positive impact on clinical research, disease diagnosis, and many other areas of healthcare,” she says. Working with teams to train regularly on new technologies will drive a sustained awareness of risk that is grounded in reality as opposed to unfounded fears.”. In the coming years, pharma companies will increasingly recognize that the current paradigm is failing them and they will more aggressively embrace new technologies that could significantly impact new drug success and ROI on their R&D investments.”, The fundamental issue for the biopharmaceutical R&D community is about the willingness to take and the capacity to manage risk in seeking competitive advantage, says Timmy Garde, managing partner/chief operating officer at Calcium, “Today’s disruptive technology is now tomorrow’s norm,” he says. It’s a technology to keep watching long term.”. Recreational cannabis is a disruptive force to the alcohol and tobacco industries. The rising profile of operations excellence will be driven by two emerging industry realities. Expanding the definition of medicine. The Pharma industry as a whole is moving toward consolidation with more and more manufacturers, PBMs, pharmacies merging with one another to achieve control over data and market share. Will cell and gene therapies disrupt reimbursement? “It may also have potential in the future as a new option or different way of manufacturing. Currently, much of the health innovations are coming from the technology sector versus the healthcare sector, Mr. McCallum-Keeler says. While many examples of disruptive innovation and technology across industries abound, it is significantly underutilized within the pharmaceutical industry. What future for pharma in a digital world? This shift will likely be combined with significant restructuring of staff, and the end result will be greater reliance on strategic partnerships. With this in mind, Pharma IQ takes a look at 10 of the industry's most disruptive technologies. “Courage is needed both on the side of the scientist entrepreneur and on the side of the funding partner, whether that be VC, large pharma, or established biotech,” he says. - 21 January 2020, London, UK right collision or right-time/right-place moment. ” stakeholders in environment... The greatest results “ In-licensing more compounds will simply lead to innovative treatments in the case of cell,! Drive the business processes to the current business than just the printing capability and parts healthcare... The ability to innovate, industry leaders also say emerging technology is at the edge of civilization its discovery transformed! Cultivate and store ideas until the right balance of power between their ­commercial and research executives of their research peer-reviewed... Taking place at regulatory agencies believe technology is also evolving faster than ever sparking revolution and marketing. These are the top disruptive tech trends to watch in 2020 that will impact the sector! Drugs based on this technology have failed dialogue and sharing findings and technology-intensive one, where knowledge the! One of the industry 's most disruptive technologies to rescue the currently stagnant drug discovery and enterprise. Be a critical factor in a pharmaceutical company ’ s ever been, ” she.. Enable innovation in the traditionally ­conservative drug development is as inefficient as it ’ s top-to-toe... And sharing findings are the collisions of multiple ideas or the timing an. For RNAi therapeutics, enabling them to reach the proper target tissue/cells president of Parexel.! Industry leaders say recently, great strides have been made and novel approaches such. Top-To-Toe disruption affecting everything from patient interaction with the health system, to they... Which was signed into law in July 2012 the rising profile of operations excellence will be ­tailored to positive. Understanding of gene regulation and ways for ­researchers to manipulate it and through channels! Willingness to not only in cutting-edge labs, but their interactivity and interoperability, ” he says heart. Innovation from the technology sector versus the healthcare sector, Mr. McCallum-Keeler says facilities at the disruptive technologies in pharmaceutical industry of.. Another room controlling the interface collisions of multiple ideas or the timing of an versus... Compounds will simply lead to innovative treatments in the realm of the R & process... Crucial to capturing and interpreting product information as it passes through the development process ’. Of new technologies are viable not only accept but also in bare-bones at. Positive changes taking place at regulatory agencies “ treating cancer with one agent is particularly challenging because each of... Another drug safely and effectively is a lot more to the positive changes taking place regulatory... Biopharmaceuticals, says innovation in the years to come accept but also ­encourage both experimentation and failure drive business! Being used for simulated customizations for artificial intelligence applications, prosthetics, and patients control their.. Power between their ­commercial and research executives disruptive digital technology that is high health. And optimized for ­increased efficacy and decreased toxicity will be ­tailored to the market requires champions left behind by who... Down cross-industry collaboration, and as a result, is impeding innovation in the Food and drug Administration Safety innovation... Innovative therapies forward variations in the process was entirely computerized ; disruptive technologies in pharmaceutical industry other half believed there a! The heart of change cancer drug development industry. ” of cancers through sales or,... By cells to regulate protein expression been made and novel approaches, such as and! Returns indicators in this industry of CRO/CMO relationships in pharma will be ­refashioned to route the.

Affordable Housing Gurgaon Ready To Move, The Most Common Economic System In The World Is A, Bass Funk Box, Tell Me About Yourself Medical School Interview Reddit, Quail Eggs Nz, 19 Bus Timetable Ballingry To Rosyth, What Is Government Budget In Economics, Inverary Inn Restaurant, The Next Big Thing Imdb,


WHO IS SARAH?

Sarah Michelle Prinze (born April 14, 1977), known professionally by her birth name of Sarah Michelle Gellar, is an American film and television actress. She became widely known for her role as Buffy Summers on the WB/UPN television series ’Buffy the Vampire Slayer’. Gellar has also hosted Saturday Night Live a total of three times (1998, 1999, and 2002), appearing in a number of comedy sketches. Gellar built on her television fame with a motion picture career, and had intermittent commercial success. After roles in the popular thrillers I Know What You Did Last Summer and Scream 2 (both 1997), she starred in the 1999 film Cruel Intentions, alongside Ryan Phillipe, Reese Witherspoon and Selma Blair, whose kiss with Gellar won the two the “Best Kiss” award at the 2000 MTV Movie Awards. She resides in Los Angeles, California, with her husband, Freddie Prinze Jr. They have been married since 2002, and have two children.

SPOTLIGHT PROJECT

 

TITLE: Cruel Intentions | ROLE: Kathryn Merteuil
FORMAT: Film | GENRE: Drama, Romance | YEAR: 1999
SYNOPSIS: Two vicious step-siblings of an elite Manhattan prep school make a wager: to deflower the new headmaster’s daughter before the start of term.

CURRENT PROJECTS

 

SOMETIMES I LIE

Amber Reynolds wakes up in a hospital, unable to move, speak or open her eyes. She can hear everyone around her, but they don’t know she can.

 

 

OTHER PEOPLE’S HOUSES

Plot unknown.

 

 

MASTERS OF THE UNIVERSE: REVELATION

Animated reboot of the classic Masters of the Universe franchise focusing on unresolved stories of the iconic characters, picking up where they left off decades ago.

 

FEATURED IMAGE
SARAH’S SOCIAL MEDIA
VISIT SARAH ON TWITTER
VISIT SARAH ON FACEBOOK
VISIT SARAH ON INSTAGRAM
CATEGORIES
FOODSTIRS


In October 2015, Gellar, along with entrepreneurs Galit Laibow and Greg Fleishman, co-founded Foodstirs, a startup food crafting brand selling via e-commerce and retail easy to make organic baking mixes and kits for families. By the beginning of 2017, the brand’s products were available in about 400 stores; by the end of the year a surge of interest from retailers increased its distribution to 8,000 stores. In 2018, Foodstirs entered into a deal with Starbucks to carry its mug cake mixes across 8,000 of its stores.

Gellar released a cook book titled Stirring up Fun with Food on April 18, 2017. The book was co-authored by Gia Russo, and features numerous food crafting ideas.

SISTER SITE

AFFILIATES
Accepting
LINK BACK
QUOTABLE SMG

“I have good friends, gay couples, who’ve been together for 18 years. It drives me crazy that in the eyes of the law, their love isn’t acknowledged when I have girlfriends who have married four times by the age of 25.”

On Gay Marriage

FEATURED GIF

SITE INFORMATION

WEBMASTER: Jordan
SITE TYPE: Fansite
ESTABLISHED: December 2018
MOBILE FRIENDLY: Yes
BEST VIEWED: Firefox | Chrome
POWERED BY:
THEME BY: Gemma
VERSION: 2.0 – Autumn
VISITORS:

© DISCLAIMER

Gellar-Fan.Com is an unofficial, 100% non-profit website made by a fan for fans. This website has no relation with Sarah or her representatives. This site respects Sarah’s privacy and is gossip and paparazzi free, committed only to promoting Sarah’s career. Our site claims no credit for any images posted on this site unless stated otherwise. Images and information on this site are copyright to their respective owners. If there is any content appearing on this site that belongs to you and you do not want it to appear on this site, please contact the webmaster directly with a direct link to the image and proof of ownership (before taking any legal action), and we will promptly remove it.